XBI
State Street SPDR S&P Biotech ETF
ETF
$154.43−0.08 (−0.05%)Close Oct 2, 2026
Adjusted price
+51.18% total return, past year
Key statistics
- Expense ratio
- 0.35%
- 52-week range
- $103.60$169.55
- From all-time high
- −11.24%
- Max drawdown
- −63.89%
- Volatility
- 30.55%
- Sharpe ratio
- 0.52
- Beta (5Y monthly)
- 0.83
- Median dollar volume
- $1.34B
- First close
- Feb 6, 2006
Returns
Total
- 1M
- −6.6%
- YTD
- +26.8%
- 1Y
- +51.2%
Per year
- 3Y
- +30.1%
- 5Y
- +4.3%
- 10Y
- +9.0%
- 20Y
- +12.5%
- Since 2006
- +11.8%
Fund facts
As of Jun 30, 2026- Net assets
- $10.7B
- Holdings
- 161
- Top 10 holdings
- 18.0%
- Stocks
- 99.9%
- Cash
- 5.9%
Sectors
- Health Care
- 95.0%
- Consumer Discretionary
- 1.2%
- Information Technology
- 0.2%
- Other
- 3.5%
Top holdings
| Holding | Weight (%) |
|---|---|
| State Street Global Advisors | 5.9 |
| Apogee Therapeutics Inc | 1.5 |
| MRNAModerna, Inc. | 1.4 |
| TWSTTwist Bioscience Corporation | 1.4 |
| ORKAOruka Therapeutics, Inc. | 1.4 |
| KYMRKymera Therapeutics, Inc. | 1.4 |
| VKTXViking Therapeutics, Inc. | 1.3 |
| PRAXPraxis Precision Medicines, Inc. | 1.3 |
| ERASErasca, Inc. | 1.3 |
| RVMDRevolution Medicines, Inc. | 1.2 |
Annual returns
2006 from Feb 6 · 2026 through Oct 2